Boehringer Ingelheim and LEO Pharma enter partnership to commercialize and further develop SPEVIGO® (spesolimab) ...

LEO has plans for Spevigo beyond generalised pustular psoriasis as it looks to boost its dermatological pipeline.

LEO is claiming global commercial rights to Spevigo for GPP but will also collaborate with Boehringer on potential follow-up ...

Boehringer Ingelheim, one of the industry leading investors in research and development in innovative life expectancy therapies, announced a $105 million (€90 million) global license and transfer ...

LEO Pharma acquires global rights to Spevigo for $105M, boosting its dermatology pipeline and expanding access for patients ...

USA: Researchers have found in a recent observational study that patients with generalized pustular psoriasis (GPP) face a ...

For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...

The agreement grants LEO Pharma exclusive rights to the branded form of spesolimab for generalized pustular psoriasis and ...

Pustular Psoriasis Types There are multiple types of pustular psoriasis. They fall into two broad categories, generalized or localized, depending on whether it affects a large area or is more limited.

LEO Pharma A/S agreed to acquire the global rights for skin disease drug Spevigo from Boehringer Ingelheim GmbH, as the ...

Generalized pustular psoriasis (GPP) is a severe form of pustular psoriasis, a group of conditions known for causing breakouts of painful pus-filled lesions (pustules).

Genetic pustular psoriasis can develop due to a combination of environmental factors and genetic traits, with stress and infection as potential triggers.